Patent Grant
11486011
This Application is a 371 of PCT/NO2018/050328 filed on Dec. 21, 2018 which, in turn, claimed the priority of Norwegian Patent Application No. 20172065 filed on Dec. 29, 2017, both applications are incorporated herein by reference.
The present invention relates to a ferrosilicon based inoculant for the manufacture of cast iron with spheroidal graphite and to a method for production of the inoculant.
Cast iron is typically produced in cupola or induction furnaces, and generally contain between 2 to 4 percent carbon. The carbon is intimately mixed with the iron and the form which the carbon takes in the solidified cast iron is very important to the characteristics and properties of the iron castings. If the carbon takes the form of iron carbide, then the cast iron is referred to as white cast iron and has the physical characteristics of being hard and brittle, which in most applications is undesirable. If the carbon takes the form of graphite, the cast iron is soft and machinable.
Graphite may occur in cast iron in the lamellar, compacted or spheroidal forms. The spheroidal shape produces the highest strength and most ductile type of cast iron.
The form that the graphite takes as well as the amount of graphite versus iron carbide, can be controlled with certain additives that promote the formation of graphite during the solidification of cast iron. These additives are referred to as nodularisers and inoculants and their addition to the cast iron as nodularisation and inoculation, respectively. In cast iron production formation iron carbide, especially in thin sections, is often a challenge. The formation of iron carbide is brought about by the rapid cooling of the thin sections as compared to the slower cooling of the thicker sections of the casting. The formation of iron carbide in a cast iron product is referred to in the trade as “chill”. The formation of chill is quantified by measuring “chill depth” and the power of inoculant to prevent chili and reduce chill depth is a convenient way in which to measure and compare the power of inoculants, especially in grey irons. In nodular iron, the power of inoculants is usually measured and compared using the graphite nodule number density.
As the industry develops there is a need for stronger materials. This means more alloying with carbide promoting elements such as Cr, Mn, V, Mo, etc., and thinner casting sections and lighter design of castings. There is therefore a constant need to develop inoculants that reduce chill depth and improve machinability of grey cast irons as well as increase the number density of graphite spheroids in ductile cast irons. The exact chemistry and mechanism of inoculation and why inoculants function as they do in different cast iron melts is not completely understood, therefore a great deal of research goes into providing the industry with new and improved inoculants.
It is thought that calcium and certain other elements suppress the formation of iron carbide and promote the formation of graphite. A majority of inoculants contain calcium. The addition of these iron carbide suppressants is usually facilitated by the addition of a ferrosilicon alloy and probably the most widely used ferrosilicon alloys are the high silicon alloys containing 70 to 80% silicon and the low silicon alloy containing 45 to 55% silicon. Elements which commonly may be present in inoculants, and added to the cast iron as a ferrosilicon alloy to stimulate the nucleation of graphite in cast iron, are e.g. Ca, Ba, Sr, Al, rare earth metals (RE), Mg, Mn, Bi, Sb, Zr and Ti.
The suppression of carbide formation is associated by the nucleating properties of the inoculant. By nucleating properties it is understood the number of nuclei formed by an inoculant. A high number of nuclei formed results in an increased graphite nodule number density and thus improves the inoculation effectiveness and improves the carbide suppression. Further, a high nucleation rate may also give better resistance to fading of the inoculating effect during prolonged holding time of the molten iron after inoculation. Fading of inoculation can be explained by the coalescing and re-solution of the nuclei population which causes the total number of potential nucleation sites to be reduced.
U.S. Pat. No. 4,432,793 discloses an inoculant containing bismuth, lead and/or antimony. Bismuth, lead and/or antimony are known to have high inoculating power and to provide an increase in the number of nuclei. These elements are also known to be anti-spheroidizing elements, and the increasing presence of these elements in cast iron is known to cause degeneration of the spheroidal graphite structure of graphite. The inoculant according to U.S. Pat. No. 4,432,793 is a ferrosilicon alloy containing from 0.005% to 3% rare earths and from 0.005% to 3% of one of the metallic elements bismuth, lead and/or antimony alloyed in the ferrosilicon.
U.S. patent application No. 2015/0284830 relates to an inoculant alloy for treating thick cast-iron parts, containing between 0.005 and 3 wt % of rare earths and between 0.2 and 2 wt % Sb. Said US 2015/0284830 discovered that antimony, when allied to rare earths in a ferrosilicon-based alloy, would allow an effective inoculation, and with the spheroids stabilized, of thick parts without the drawbacks of pure antimony addition to the liquid cast-iron. The inoculant according to US 2015/0284830 is described to be typically used in the context of an inoculation of a cast-iron bath, for pre-conditioning said cast-iron as well as a nodularizer treatment. An inoculant according to US 2015/0284830 contains (by wt %) 65% Si, 1.76% Ca, 1.23% Al, 0.15% Sb, 0.16% RE, 7.9% Ba and balance iron.
From WO 95/24508 it is known a cast iron inoculant showing an increased nucleation rate. This inoculant is a ferrosilicon based inoculant containing calcium and/or strontium and/or barium, less than 4% aluminium and between 0.5 and 10% oxygen in the form of one or more metal oxides. It was, however found that the reproducibility of the number of nuclei formed using the inoculant according to WO 95/24508 was rather low. In some instances a high number of nuclei are formed in the cast iron, but in other instances the numbers of nuclei formed are rather low. The inoculant according to WO 95/24508 has for the above reason found little use in practice.
From WO 99/29911 it is known that the addition of sulphur to the inoculant of WO 95/24508 has a positive effect in the inoculation of cast iron and increases the reproducibility of nuclei.
In WO 95/24508 and WO 99/29911 iron oxides; FeO, Fe2O3 and Fe3O4, are the preferred metal oxides. Other metal oxides mentioned in these patent applications are SiO2, MnO, MgO, CaO, Al2O3, TiO2 and CaSiO3, CeO2, ZrO2. The preferred metal sulphide is selected from the group consisting of FeS, FeS2, MnS, MgS, CaS and CuS.
From US application No. 2016/0047008 it is known a particulate inoculant for treating liquid cast-iron, comprising, on the one hand, support particles made of a fusible material in the liquid cast-iron, and on the other hand, surface particles made of a material that promotes the germination and the growth of graphite, disposed and distributed in a discontinuous manner at the surface of the support particles, the surface particles presenting a grain size distribution such that their diameter d50 is smaller than or equal to one-tenth of the diameter d50 of the support particles. The purpose of the inoculant in said US 2016' is inter alia indicated for the inoculation of cast-iron parts with different thicknesses and low sensibility to the basic composition of the cast-iron.
Thus, there is a desire to provide a high performance inoculant forming a high number of nuclei, which results in a high graphite nodule number density. A further desire is to provide an inoculant which may give better resistance to fading of the inoculating effect during prolonged holding time of the molten iron after inoculation. Another desire is to provide a FeSi based inoculant containing antimony, without the drawbacks of the prior art. At least some of the above desires are met with the present invention, as well as other advantages, which will become evident in the following description.
In a first aspect, the present invention relates to an inoculant for the manufacture of cast iron with spheroidal graphite wherein said inoculant comprises
a particulate ferrosilicon alloy consisting of between about 40 to 80% by weight Si; 0.02-10% by weight Ca; 0-15% by weight rare earth metal; 0-5% by weight Al; 0-5% by weight Sr; 0-5% by weight Mg; 0-12% by weight Ba; 0-10% by weight Zr; 0-10% by weight Ti; 0-10% by weight Mn; the balance being Fe and incidental impurities in the ordinary amount, wherein at least one, or the sum, of elements Ba, Sr, Zr, Mn, or Ti is (are) present in an amount of at least 0.05% by weight, and wherein said inoculant additionally contains, by weight, based on the total weight of inoculant: 0.1 to 15% by weight of particulate Sb2O3.
In an embodiment, the ferrosilicon alloy comprises between 45 and 60% by weight of Si. In another embodiment of the inoculant the ferrosilicon alloy comprises between 60 and 80% by weight of Si.
In an embodiment, the rare earth metals include Ce, La, Y and/or mischmetal. In an embodiment, the ferrosilicon alloy comprises up to 10% by weight of rare earth metal. In an embodiment, the ferrosilicon alloy comprises between 0.02 and 5% by weight of Ca. In another embodiment, the ferrosilicon alloy comprises between 0.5 and 3% by weight of Ca. In an embodiment, the ferrosilicon alloy comprises between 0 and 3% by weight of Sr. In a further embodiment, the ferrosilicon alloy comprises between 0.2 and 3% by weight of Sr. In an embodiment, the ferrosilicon alloy comprises between 0 and 5% by weight of Ba. In a further embodiment, the ferrosilicon alloy comprises between 0.1 and 5% by weight of Ba. In an embodiment, the ferrosilicon alloy comprises between 0.5 and 5% by weight Al. In an embodiment, the ferrosilicon alloy comprises up to 6% by weight of Mn and/or Ti and/or Zr. In an embodiment, the ferrosilicon alloy comprises less than 1% by weight Mg.
In an embodiment the at least one, or the sum, of elements Ba, Sr, Zr, Mn, or Ti is (are) present in an amount of at least 0.1% by weight.
In an embodiment, the inoculant comprises between 0.5 and 10% of particulate Sb2O3.
In an embodiment, the inoculant is in the form of a blend or a mechanical/physical mixture of the particulate ferrosilicon alloy and the particulate Sb2O3.
In an embodiment, the particulate Sb2O3 is present as a coating compound on the particulate ferrosilicon based alloy.
In an embodiment, the particulate Sb2O3 is mechanically mixed or blended with the particulate ferrosilicon based alloy, in the presence of a binder.
In an embodiment, the inoculant is in the form of agglomerates made from a mixture of the particulate ferrosilicon alloy and the particulate Sb2O3, in the presence of a binder.
In an embodiment, the inoculant is in the form of briquettes made from a mixture of the particulate ferrosilicon alloy and the particulate Sb2O3, in the presence of a binder.
In an embodiment, the particulate ferrosilicon based alloy and the particulate Sb2O3 are added separately but simultaneously to liquid cast iron.
In a second aspect the present invention relates to a method for producing an inoculant according to the present invention, the method comprises: providing a particulate base alloy comprising between 40 and 80% by weight of Si, 0.02-10% by weight of Ca; 0-5% by weight of Sr; 0-12% by weight of Ba; 0-15% by weight of rare earth metal; 0-5% by weight of Mg; 0-5% by weight of Al; 0-10% by weight of Mn; 0-10% by weight of Ti; 0-10% by weight of Zr; the balance being Fe and incidental impurities in the ordinary amount, wherein at least one, or the sum, of elements Ba, Sr, Zr, Mn, or Ti is (are) present in an amount of at least 0.05% by weight, and wherein said inoculant additionally contains, by weight, based on the total weight of inoculant: 0.1 to 15% by weight of particulate Sb2O3, to produce said inoculant.
In an embodiment of the method the particulate Sb2O3 is mechanically mixed or blended with the particulate base alloy.
In an embodiment of the method the particulate Sb2O3 is mechanically mixed or blended with the particulate base alloy in the presence of a binder. In a further embodiment of the method, the mechanically mixed or blended particulate base alloy and the particulate Sb2O3, in the presence of a binder, are further formed into agglomerates or briquettes.
In another aspect, the present invention relates to the use of the inoculant as defined above in the manufacturing of cast iron with spheroidal graphite, by adding the inoculant to the cast iron melt prior to casting, simultaneously to casting or as an in-mould inoculant.
In an embodiment of the use of the inoculant, the particulate ferrosilicon based alloy and the particulate Sb2O3 are added as a mechanical/physical mixture or a blend to the cast iron melt.
In an embodiment of the use of the inoculant, the particulate ferrosilicon based alloy and the particulate Sb2O3 are added separately but simultaneously to the cast iron melt.
According to the present invention a high potent inoculant is provided, for the manufacture of cast iron with spheroidal graphite. The inoculant comprises a FeSi base alloy wherein at least one of, or the sum of, elements Ba, Sr, Zr, Mn, or Ti, is present in an amount of at least 0.05% by weight, combined with particulate antimony oxide (Sb2O3). The inoculant according to the present invention is easy to manufacture and it is easy to control and vary the amount of Sb in the inoculant. Complicated and costly alloying steps are avoided, and further, thus the inoculant can be manufactured at a lower cost compared to prior art inoculants containing Sb.
In the manufacturing process for producing ductile cast iron with spheroidal graphite the cast iron melt is normally treated with a nodulariser, e.g. by using an MgFeSi alloy, prior to the inoculation treatment. The nodularisation treatment has the objective to change the form of the graphite from flake to nodule when it is precipitating and subsequently growing. The way this is done is by changing the interface energy of the interface graphite/melt. It is known that Mg and Ce are elements that change the interface energy, Mg being more effective than Ce. When Mg is added to a base iron melt, it will first react with oxygen and sulphur, and it is only the “free magnesium” that will have a nodularising effect. The nodularisation reaction is violent and results in agitation of the melt, and it generates slag floating on the surface. The violence of the reaction will result in most of the nucleation sites for graphite that were already in the melt (introduced by the raw materials) and other inclusions being part of the slag on the top and removed. However some MgO and MgS inclusions produced during the nodularisation treatment will still be in the melt. These inclusions are not good nucleation sites as such.
The primary function of inoculation is to prevent carbide formation by introducing nucleation sites for graphite. In addition to introducing nucleation sites the inoculation also transform the MgO and MgS inclusions formed during the nodularisation treatment into nucleation sites by adding a layer (with Ca, Ba or Sr) on the inclusions.
In accordance with the present invention, the particulate FeSi base alloys should comprise from 40 to 80% by weight Si. A pure FeSi alloy is a weak inoculant, but is a common alloy carrier for active elements, allowing good dispersion in the melt. Thus, there exists a variety of known FeSi alloy compositions for inoculants. Conventional alloying elements in a FeSi alloy inoculant include Ca, Ba, Sr, Al, Mg, Zr, Mn, Ti and RE (especially Ce and La). The amount of the alloying elements may vary. Normally, inoculants are designed to serve different requirements in grey, compacted and ductile iron production. The inoculant according to the present invention may comprise a FeSi base alloy with a silicon content of about 40-80% by weight. The alloying elements may comprise about 0.02-10% by weight of Ca; about 0-5% by weight of Sr; about 0-12% by weight of Ba; about 0-15% by weight of rare earth metal; about 0-5% by weight of Mg; about 0-5% by weight of Al; about 0-10% by weight of Mn; about 0-10% by weight of Ti; about 0-10% by weight of Zr; and the balance being Fe and incidental impurities in the ordinary amount, where at least one, or the sum, of the elements Ba, Sr, Zr, Mn, or Ti is (are) present in an amount of at least about 0.05%, e.g. about 0.1%, by weight.
The FeSi base alloy may be a high silicon alloy containing 60 to 80% silicon or a low silicon alloy containing 45 to 60% silicon. Silicon is normally present in cast iron alloys, and is a graphite stabilizing element in the cast iron, which forces carbon out of the solution and promotes the formation of graphite. The FeSi base alloy should have a particle size lying within the conventional range for inoculants, e.g. between 0.2 to 6 mm. It should be noted that smaller particle sizes, such as fines, of the FeSi alloy may also be applied in the present invention, to manufacture the inoculant. When using very small particles of the FeSi base alloy the inoculant may be in the form of agglomerates (e.g. granules) or briquettes. In order to prepare agglomerates and/or briquettes of the present inoculant, the Sb2O3 particles are mixed with the particulate ferrosilicon alloy by mechanical mixing or blending, in the presence of a binder, followed by agglomeration of the powder mixture according to known methods. The binder may e.g. be a sodium silicate solution. The agglomerates may be granules with suitable product sizes, or may be crushed and screened to the required final product sizing.
A variety of different inclusions (sulphides, oxides, nitrides and silicates) can form in the liquid state. The sulphides and oxides of the group IIA-elements (Mg, Ca, Sr and Ba) have very similar crystalline phases and high melting points. The group IIA elements are known to form stable oxides in liquid iron; therefore inoculants, and nodularisers, based on these elements are known to be effective deoxidizers. Calcium is the most common trace element in ferrosilicon inoculants. In accordance with the invention, the particulate FeSi based alloy comprises between about 0.02 to about 10% by weight of calcium. In some applications it is desired to have low content of Ca in the FeSi base alloy, e.g. from 0.02 to 0.5% by weight. In other applications the Ca content could be higher, e.g. from 0.5 to 5% by weight. A high level of Ca may increase slag formation, which is normally not desired. A plurality of inoculants comprise about 0.5 to 3% by weight of Ca in the FeSi alloy. The FeSi base alloy should comprise up to about 5% by weight of strontium. A Sr amount of 0.2-3% by weight is typically suitable. Barium may be present in an amount up to about 12% by weight in the FeSi inoculant alloy. Ba is known to give better resistance to fading of the inoculating effect during prolonged holding time of the molten iron after inoculation, and gives better efficiencies over a wider temperature range. Many FeSi alloy inoculants comprise about 0.1-5% by weight of Ba. If barium is used in conjunction with calcium the two may act together to give a greater reduction in chill than an equivalent amount of calcium.
Magnesium may be present in an amount up to about 5% by weight in the FeSi inoculant alloy. However, as Mg normally is added in the nodularisation treatment for the production of ductile iron, the amount of Mg in the inoculant may be low, e.g. up to about 0.1% by weight.
The FeSi base alloy may comprise up to 15% by weight of rare earths metals (RE). RE includes at least Ce, La, Y and/or mischmetal. Mischmetal is an alloy of rare-earth elements, typically comprising approx. 50% Ce and 25% La, with small amounts of Nd and Pr. Lately heavier rare earth metals are often removed from the mischmetal, and the alloy composition of mischmetal may be about 65% Ce and about 35% La, and traces of heavier RE metals, such as Nd and Pr. Additions of RE are frequently used to restore the graphite nodule count and nodularity in ductile iron containing subversive elements, such as Sb, Pb, Bi, Ti etc. In some inoculants the amount of RE is up to 10% by weight. Excessive RE may in some instances lead to chunky graphite formations. Thus, in some applications the amount of RE should be lower, e.g. between 0.1-3% by weight. Preferably the RE is Ce and/or La.
Aluminium has been reported to have a strong effect as a chill reducer. Al is often combined with Ca in a FeSi alloy inoculants for the production of ductile iron. In the present invention, the Al content should be up to about 5% by weight, e.g. from 0.1-5%.
Zirconium, manganese and/or titanium are also often present in inoculants. Similar as for the above mentioned elements, the Zr, Mn and Ti play an important role in the nucleation process of the graphite, which is assumed to be formed as a result of heterogeneous nucleation events during solidification. The amount of Zr in the FeSi base alloy may be up to about 10% by weight, e.g. up to 6% by weight. The amount of Mn in the FeSi base alloy may be up to about 10% by weight, e.g. up to 6% by weight. The amount of Ti in the FeSi base alloy may also be up to about 10% by weight, e.g. up to 6% by weight.
Antimony is known to have high inoculating power and to provide an increase in the number of nuclei. However, the presence of small amounts Sb in the melt (also called subversive element) might reduce nodularity. This negative effect can be neutralized by using Ce or other RE metal. According to the present invention, the amount of particulate Sb2O3 should be from 0.1 to 15% by weight based on the total amount of the inoculant. In some embodiments the amount of Sb2O3 is 0.5-10% by weight. Good results are also observed when the amount of Sb2O3 is from about 0.5 to about 3.5% by weight, based on the total weight of inoculant. The Sb2O3 particles should have a small particle size, i.e. micron size, e.g. 10-150 μm, resulting in very quick melting and/or dissolution of the Sb2O3 particles when introduced in the cast iron melt.
Adding Sb in the form of Sb2O3 particles instead of alloying Sb with the FeSi alloy, provide several advantages. Although Sb is a powerful inoculant, the oxygen is also of importance for the performance of the inoculant. Another advantage is the good reproducibility, and flexibility, of the inoculant composition since the amount and the homogeneity of particulate Sb2O3 in the inoculant are easily controlled. The importance of controlling the amount of inoculants and having a homogenous composition of the inoculant is evident given the fact that antimony is normally added at a ppm level. Adding an inhomogeneous inoculant may result in wrong amounts of inoculating elements in the cast iron. Still another advantage is the more cost effective production of the inoculant compared to methods involving alloying antimony in a FeSi based alloy.
It should be understood that the composition of the FeSi base alloy may vary within the defined ranges, and the skilled person will know that the amounts of the alloying elements add up to 100%. There exists a plurality of conventional FeSi based inoculant alloys, and the skilled person would know how to vary the FeSi base composition based on these, within the defined limits.
The addition rate of the inoculant according to the present invention to a cast iron melt is typically from about 0.1 to 0.8% by weight. The skilled person would adjust the addition rate depending on the levels of the elements, e.g. an inoculant with high Sb will typically need a lower addition rate.
The present inoculant is produced by providing a particulate FeSi base alloy having the composition as defined herein, and adding to the said particulate base the particulate Sb2O3, to produce the present inoculant. The Sb2O3 particles may be mechanically/physically mixed with the FeSi base alloy particles. Any suitable mixer for mixing/blending particulate and/or powder materials may be used. The mixing may be performed in the presence of a suitable binder, however it should be noted that the presence of a binder is not required. The Sb2O3 particles may also be blended with the FeSi base alloy particles, providing a homogenously mixed inoculant. Blending the Sb2O3 particles with the FeSi base alloy particles, may form a stable coating on the FeSi base alloy particles. It should however be noted that mixing and/or blending the Sb2O3 particles with the particulate FeSi base alloy is not mandatory for achieving the inoculating effect. The particulate FeSi base alloy and Sb2O3 particles may be added separately but simultaneously to the liquid cast iron. The inoculant may also be added as an in-mould inoculant. The inoculant particles of FeSi alloy and Sb2O3 particles may also be formed to agglomerates or briquettes according to generally known methods.
The following Examples show that the addition of Sb2O3 together with FeSi base alloy particles results in a high nodule number density when the inoculant is added to cast iron. A high nodule count allows reducing the amount of inoculant necessary to achieve the desired inoculating effect.
All test samples were analysed with respect to the microstructure to determine the nodule density. The microstructure was examined in one tensile bar from each trial according to ASTM E2567-2016. Particle limit was set to >10 μm. The tensile samples were Ø28 mm cast in standard moulds according to ISO1083-2004, and were cut and prepared according to standard practice for microstructure analysis before evaluating by use of automatic image analysis software. The nodule density (also denoted nodule number density) is the number of nodules (also denoted nodule count) per mm2, abbreviated N/mm2.
One cast iron melt, Melt AJ of 275 kg was melted and treated by 1.20-1.25 wt-% MgFeSi nodulariser alloy of the composition: 46 wt % Si, 4.33 wt % Mg, 0.69 wt % Ca, 0.44 wt % RE, 0.44 wt % Al, balance Fe and incidental impurities, in a tundish cover ladle. 0.7% by weight steel chips were used as cover. From the treatment ladle, the melt was poured over to pouring ladles. Addition rates for the inoculants were 0.2% by weight added to each pouring ladle. The MgFeSi treatment temperature was 1500° C. and pouring temperatures were 1380-1352° C. The holding time from filling the pouring ladles to pouring was 1 minute for all trials.
The test inoculants had three different ferrosilicon base alloys of the following compositions:
Inoculant A: 74 wt % Si, 2.42 wt % Ca, 1.73 wt % Zr, 1.23 wt % Al, balance Fe and incidental impurities in the ordinary amount.
Inoculant B: 68.2 wt % Si, 0.95 wt % Ca, 0.94 wt % Ba, 0.93 wt % Al, balance Fe and incidental impurities in the ordinary amount.
Inoculant C: 64.4 wt % Si, 1.51 wt % Ca, 0.53 wt % Ba, 4.17 wt % Zr, 3.61 wt % Mn, 1.29 wt % Al, balance Fe and incidental impurities in the ordinary amount.
The base ferrosilicon alloy particles (Inoculant A, B and C) were coated by particulate Sb2O3 by mechanically mixing to obtain a homogenous mixture.
The final cast iron chemical composition for all treatments were within 3.5-3.7 wt % C, 2.3-2.5 wt % Si, 0.29-0.31 wt % Mn, 0.009-0.011 wt % S, 0.04-0.05 wt % Mg.
The added amounts of particulate Sb2O3, to the FeSi base alloy (Inoculant A, B and C) are shown in Table 1. The amounts of Sb2O3 is the amount of the compound, based on the total weight of the inoculants in all tests.
The nodule density in the cast irons from the inoculation trials in Melt AJ are shown in
A 275 kg melt was produced and treated by 1.20-1.25 wt-% MgFeSi nodulariser in a tundish cover ladle. The MgFeSi nodularizing alloy had the following composition by weight: 4.33 wt % Mg, 0.69 wt % Ca, 0.44 wt % RE, 0.44 wt % Al, 46 wt % Si, the balance being iron and incidental impurities in the ordinary amount. 0.7% by weight steel chips were used as cover. Addition rate for all inoculants were 0.2% by weight added to each pouring ladle. The nodulariser treatment temperature was 1500° C. and the pouring temperatures were 1365-1359° C. Holding time from filling the pouring ladles to pouring was 1 minute for all trials. The tensile samples were Ø28 mm cast in standard moulds and were cut and prepared according to standard practice before evaluating by use of automatic image analysis software.
The inoculant had a base FeSi alloy composition 74 wt % Si, 1.23 wt % Al, 2.42 wt % Ca, 1.73 wt % Zr, the remaining being iron and incidental impurities in the ordinary amount, herein denoted Inoculant A. Particulate antimony oxide in the amount as indicated in Table 2 was added to the base FeSi alloy particles (Inoculant A) and by mechanically mixing, a homogeneous mixture was obtained.
The final iron had a chemical composition of 3.84 wt % C, 2.32 wt % Si, 0.20 wt % Mn, 0.017 wt % S, 0.038 wt % Mg.
The added amounts of particulate Sb2O3, to the FeSi base alloy Inoculant A are shown in Table 2. The amounts of Sb2O3 are based on the total weight of the inoculants in all tests.
The nodule density in the cast irons from the inoculation trials in Melt CH are shown in
Having described different embodiments of the invention it will be apparent to those skilled in the art that other embodiments incorporating the concepts may be used. These and other examples of the invention illustrated above and in the accompanying drawings are intended by way of example only and the actual scope of the invention is to be determined from the following claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20172065 | Dec 2017 | NO | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/NO2018/050328 | 12/21/2018 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2019/132672 | 7/4/2019 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4432793 | Hilaire et al. | Feb 1984 | A |
| 5733502 | Margaria et al. | Mar 1998 | A |
| 20150284830 | Fay et al. | Oct 2015 | A1 |
| 20160047008 | Margaria et al. | Feb 2016 | A1 |
| 20200340069 | Ott | Oct 2020 | A1 |
| 20200399724 | Ott | Dec 2020 | A1 |
| 20200399726 | Ott | Dec 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 1213408 | Apr 1999 | CN |
| 1281513 | Jan 2001 | CN |
| 1687464 | Oct 2005 | CN |
| 1833041 | Sep 2006 | CN |
| 101525719 | Sep 2009 | CN |
| 101608280 | Dec 2009 | CN |
| 102002548 | Apr 2011 | CN |
| 103418757 | Dec 2013 | CN |
| 103484749 | Jan 2014 | CN |
| 103898268 | Aug 2015 | CN |
| 105401049 | Mar 2016 | CN |
| 105950953 | Sep 2016 | CN |
| 106834588 | Jun 2017 | CN |
| 107354370 | Nov 2017 | CN |
| 107400750 | Nov 2017 | CN |
| 107829017 | Mar 2018 | CN |
| 1126037 | Aug 2001 | EP |
| 1296048 | Nov 1972 | GB |
| S5943843 | Mar 1984 | JP |
| 2000512686 | Sep 2000 | JP |
| 2040575 | Jul 1995 | RU |
| 872563 | Oct 1981 | SU |
| 1036783 | Aug 1983 | SU |
| 1047969 | Oct 1983 | SU |
| 1640193 | Apr 1991 | SU |
| 9524508 | Sep 1995 | WO |
| 9726376 | Jul 1997 | WO |
| 9929911 | Jun 1999 | WO |
| 02081758 | Oct 2002 | WO |
| 2006068487 | Jun 2006 | WO |
| 2018004356 | Jan 2018 | WO |
| Entry |
|---|
| Search Report for Corresponding Norwegian Application No. 20172061(2 Pages) (dated Jul. 20, 2018). |
| International Search Report and Written Opinion for Corresponding International Application No. PCT/NO2018/050324 (11 Pages) (dated Apr. 4, 2019). |
| International Search Report and Written Opinion for Corresponding International Application No. PCT/NO2018/050327 (10 Pages) (dated Apr. 17, 2019). |
| Search Report for Corresponding Norwegian Application No. 20172064(2 Pages) (dated Jul. 20, 2018). |
| Search Report for Corresponding Taiwanese Application No. 107147351 (1 Page) (dated Oct. 15, 2019). |
| International Preliminary Report on Patentability for Corresponding international Application No. PCT/NO2018/050327 (16 Pages) (dated Dec. 4, 2019). |
| International Search Report and Written Opinion for Corresponding International Application No. PCT/NO2018/050325 (9 Pages) (dated Apr. 15, 2019). |
| Search Report for Corresponding Norwegian Application No. 20172062 (2 Pages) (dated Jul. 20, 2018). |
| Search Report for Corresponding Taiwanese Application No. 107147349 (1 Page) (dated Aug. 1, 2019). |
| International Search Report and Written Opinion for Corresponding International Application No. PCT/NO2018/050326 (10 Pages) (dated Apr. 26, 2019). |
| Search Report for Corresponding Norwegian Application No. 20172063 (2 Pages) (dated Jul. 20, 2018). |
| Search Report for Corresponding Taiwanese Application No. 107147350 (1Page) (dated Oct. 15, 2019). |
| Search Report for Corresponding Norwegian Application No. 20172065 (2 Pages) (dated Jul. 20, 2018). |
| Search Report for Corresponding Taiwanese Application No. 107147348 (1 Page) (dated Oct. 15, 2019). |
| International Search Report and Written Opinion for Corresponding International Application No. PCT/NO2018/050328 (10 Pages) (dated Apr. 26, 2019). |
| Search Report for Corresponding Russian Application No. 2020124947/05 dated Dec. 14, 2021. |
| Office Action for Corresponding Japanese Application No. 2020-536543 dated Jan. 12, 2022. |
| Search Report for Corresponding Chinese Application No. 201880083904.1; 3 Pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20200399725 A1 | Dec 2020 | US |
